Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.amepre.2021.03.009 http://scihub22266oqcxt.onion/10.1016/j.amepre.2021.03.009 34020848!8131393!34020848     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Prev+Med 2021 ; 61 (3): 386-393 Nephropedia Template TP {{tp|p=34020848|t=2021. Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U S |pdf=|usr=}}{{34020848}} gab.com Text Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U S JO: Am J Prev Med http://www.kidney.de/pget.php?&tw=1&pmid=34020848 #FOAvip INTRODUCTION: This study evaluates the impact of the COVID-19 pandemic on testing for common sexually transmitted infections. Specifically, changes are measured in chlamydia and gonorrhea testing and case detection among patients aged 14-49 years during the COVID-19 pandemic. METHODS: U.S. chlamydia and gonorrhea testing and positivity were analyzed on the basis of >18.6 million tests (13.6 million tests for female patients and 4.7 million tests for male patients) performed by a national reference clinical laboratory from January 2019 through June 2020. RESULTS: Chlamydia and gonorrhea testing reached a nadir in early April 2020, with decreases (relative to the baseline level) of 59% for female patients and 63% for male patients. Declines in testing were strongly associated with increases in weekly positivity rates for chlamydia (R(2)=0.96) and gonorrhea (R(2)=0.85). From March 2020 through June 2020, an expected 27,659 (26.4%) chlamydia and 5,577 (16.5%) gonorrhea cases were potentially missed. CONCLUSIONS: The COVID-19 pandemic impacted routine sexually transmitted infection services, suggesting an increase in syndromic sexually transmitted infection testing and missed asymptomatic cases. Follow-up analyses will be needed to assess the long-term implications of missed screening opportunities. These findings should serve as a warning for the potential sexual and reproductive health implications that can be expected from the overall decline in testing and potential missed cases. Twit Text FOAVip Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U S ????Am J Prev Med http://www.kidney.de/pget.php?&tw=1&pmid=34020848 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34020848 #FOAvip English Wikipedia <ref>{{Cite pmid|34020848}}</ref> Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the U S #MMPMID34020848 Pinto CN; Niles JK; Kaufman HW; Marlowe EM; Alagia DP; Chi G; Van Der Pol B Am J Prev Med 2021[Sep]; 61 (3): 386-393 PMID34020848show ga INTRODUCTION: This study evaluates the impact of the COVID-19 pandemic on testing for common sexually transmitted infections. Specifically, changes are measured in chlamydia and gonorrhea testing and case detection among patients aged 14-49 years during the COVID-19 pandemic. METHODS: U.S. chlamydia and gonorrhea testing and positivity were analyzed on the basis of >18.6 million tests (13.6 million tests for female patients and 4.7 million tests for male patients) performed by a national reference clinical laboratory from January 2019 through June 2020. RESULTS: Chlamydia and gonorrhea testing reached a nadir in early April 2020, with decreases (relative to the baseline level) of 59% for female patients and 63% for male patients. Declines in testing were strongly associated with increases in weekly positivity rates for chlamydia (R(2)=0.96) and gonorrhea (R(2)=0.85). From March 2020 through June 2020, an expected 27,659 (26.4%) chlamydia and 5,577 (16.5%) gonorrhea cases were potentially missed. CONCLUSIONS: The COVID-19 pandemic impacted routine sexually transmitted infection services, suggesting an increase in syndromic sexually transmitted infection testing and missed asymptomatic cases. Follow-up analyses will be needed to assess the long-term implications of missed screening opportunities. These findings should serve as a warning for the potential sexual and reproductive health implications that can be expected from the overall decline in testing and potential missed cases. |*COVID-19[MESH] |*Chlamydia[MESH] |*Chlamydia Infections/diagnosis/epidemiology[MESH] |*Gonorrhea/diagnosis/epidemiology[MESH] |*Sexually Transmitted Diseases/epidemiology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Mass Screening[MESH] |Pandemics[MESH]Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening i(epmc).pdf DeepDyve Pubget Overpricing